

Table 3. Cost-effectiveness – base-case and sensitivity analyses*

Assumption/parameter	Base case	Sensitivity analyses	Incremental cost	Incremental QALY	ICER	ICER (% change)
<i>Ranibizumab monotherapy versus laser monotherapy</i>						
Base case	–	–	£4,191	0.17	£24,028	–
Discount rate of future costs and benefits	3.50%	0–5%	£3,593–4,383	0.16 to 0.16	£17,051–27,042	–29% to +13%
Time horizon	15 years	10–20 years	£4,738–£3,991	0.14 to 0.19	£33,139 to £21,343	+38% to –11%
Cost of blindness	£6477	–25% to +25%	£4,868– 3,515	0.17 to 0.17	£27,907–20,150	+16% to –16%
Long-term progression of VA	Declining	Constant or increasing	£4,487– 4,693	0.17 to 0.17	£26,198–28,413	+9% to +18%
Total number of ranibizumab injections	10	–4 injections to + 4 injections	£2,171– 6,774	0.17 to 0.17	£12,446–38,836	–48% to +62%
Baseline age	63 years	58 years	£3,767	0.20	£19,259	–20%
Source of utilities	RESTORE	Lloyd <i>et al.</i> [13]	£4,191	0.22	£19,238	–20%
	RESTORE	Brown <i>et al.</i> [14]	£4,191	0.19	£21,953	–9%
<i>Combination therapy versus laser monotherapy</i>						
Base case	–	–	£4,695	0.13	£36,106	–
Discounting of future costs and benefits	3.50%	0–5%	£4,271–4,828	0.16 to 0.12	£26,957–40,096	–25% to +11%
Time horizon	15 years	10–20 years	£5,133–4,507	0.10 to 0.13	£49,294–34,135	+37% to –5%
Cost of blindness	£6477	–25% to +25%	£5,050–4,340	0.13 to 0.13	£38,833–33,378	+8% to –8%
Long-term progression of VA	Declining	Constant or increasing	£5,091–5,276	0.13 to 0.12	£40,852–44,071	+13% to +22%
Total number of ranibizumab injections	9	–4 injections to + 4 injections	£3,165–7,260	0.13 to 0.13	£24,340–55,828	–33% to +55%
Baseline age	63 years	58 years	£4,393	0.15	£29,952	–17%
Source of utilities	RESTORE	Lloyd <i>et al</i> [13]	£4,695	0.16	£28,778	–20%

